International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.

Date publication

octobre 2021

Journal

JHEP reports : innovation in hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe

Tous les auteurs :
Degroote H, Piñero F, Costentin C, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas AL, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Di Benedetto F, Duque SH, Salame E, Cillo U, Gadano A, Vanlemmens C, Fagiuoli S, Rubinstein F, Burra P, Cherqui D, Silva M, Van Vlierberghe H, Duvoux C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34485882

Résumé

Good outcomes after liver transplantation (LT) have been reported after successfully downstaging to Milan criteria in more advanced hepatocellular carcinoma (HCC). We aimed to compare post-LT outcomes in patients receiving locoregional therapies (LRT) before LT according to Milan criteria and University of California San Francisco downstaging (UCSF-DS) protocol and 'all-comers'.

Mots clés

AC, all-comers, AFP, alpha-foetoprotein, All-comers, Alpha-foetoprotein, DS, downstaging, Downstaging, EASL, European Association for the Study of the Liver, HCC, hepatocellular carcinoma, HR, hazard ratio, Hepatocellular carcinoma, ITT, intention to treat, LR, liver resection, LRT, locoregional therapies, LT, liver transplantation, MC, Milan criteria, MVI, microvascular invasion, PEI, percutaneous ethanol ablation, RFA, radiofrequency ablation, SHR, subdistribution hazard ratio, TACE, transarterial chemoembolisation, UCSF downstaging protocol, UCSF-DS, University of California San Francisco downstaging, UNOS, United Network for Organ Sharing, WL, waiting list

Référence

JHEP Rep. 2021 Oct;3(5):100331